Stay updated with breaking news from Replimune Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
HC Wainwright reiterated their buy rating on shares of Replimune Group (NASDAQ:REPL – Free Report) in a report released on Tuesday morning, Benzinga reports. The brokerage currently has a $51.00 target price on the stock. Separately, Piper Sandler reiterated an overweight rating and issued a $44.00 target price on shares of Replimune Group in a […]
Replimune Group (NASDAQ:REPL – Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.75) EPS for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.05, Briefing.com reports. During the same period in the prior year, the firm earned ($0.78) earnings per share. Replimune Group Stock Up 2.8 % REPL stock […]
Replimune Group (NASDAQ:REPL – Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.75) EPS for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.05, Briefing.com reports. During the same period last year, the business earned ($0.78) earnings per share. Replimune Group Price Performance NASDAQ REPL traded up $0.54 during […]
WILMINGTON, Del.--(BUSINESS WIRE)--Aug 1, 2023--
31.07.2023 - Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, and Incyte (NASDAQ:INCY), a global biopharmaceutical company, today announced a ... Seite 1